Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Points To 5 R&D "Stars," But Antithrombotic Shines Brightest

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on

You may also be interested in...

Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix

Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.

Schering Plough’s Bridion Faces FDA Setback

Safety concerns render anesthesia injection “not approvable” in U.S.

Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition

Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts